Stay long CHF vs USD (3-month put spread) and EUR (cash). Keep short a 3-mo strangle in EURCHF against the underlying cash short. It’s important to stress we are bullish CHF for domestic, reasons (current account = 10% of GDP, private-sector capital outflow = zero).
We are thus comfortable short EURCHF even though we think the risk of a Le Pen presidency is only half the one-third chance priced by betting markets.
Nevertheless, political fear provides an opportunity to earn risk premium, hence we have sold the elevated level of EURCHF vols through a 3m strangle against underlying cash short. While low volatility tends to self-destroy over time as it leads to complacency and then leverage, which makes the system more vulnerable to even minor shocks. Partly due to post-crisis caution, credit growth at the global level has been a lot more stable in this cycle and has not accelerated.
The risk premium for low strikes has eased quite a bit this week (3m risk reversal has tightened from -4.0% to -3.25%) but even so the market over-discounts the risk of Le Pen and undervalues the SNB backstop (we expect the SNB to continue to lockdown EURCHF through unlimited intervention in the event of a Le Pen victory just as it has done over the past four weeks when it has spent 2.5% of GDP to keep EURCHF above 1.06).
USDCHF could become more vulnerable nearer April 14th when the US Treasury is due to release its bi-annual currency manipulation report. Will Treasury call a spade a spade?
Stay short a 3m strangle in EURCHF (sell a 1.0850 call and a 1.03 put).
Stay short EURCHF in cash (first entered 1.0720).
Hold a 3-month 1.0180-0.9750 USDCHF put spread.


US Futures Rise as Investors Eye Earnings, Inflation Data, and Wildfire Impacts
Bank of America Posts Strong Q4 2024 Results, Shares Rise
Gold Cracks Below $4,500 as Safe-Haven Shine Fades; Technical Breakdown Signals Sell-on-Rallies Toward $4,000
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks
Moody's Upgrades Argentina's Credit Rating Amid Economic Reforms
China's Refining Industry Faces Major Shakeup Amid Challenges
Global Markets React to Strong U.S. Jobs Data and Rising Yields
NHS shakeup: if it sounds like we’ve been here before, it’s because we have
Rice feeds billions of people – but its role in fueling climate change is growing
Goldman Predicts 50% Odds of 10% U.S. Tariff on Copper by Q1 Close
Indonesia Surprises Markets with Interest Rate Cut Amid Currency Pressure
China’s Growth Faces Structural Challenges Amid Doubts Over Data




